Health Care & Life Sciences » Pharmaceuticals | Pieris Pharmaceuticals Inc.

Pieris Pharmaceuticals Inc.

Pieris Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
54.03 M
Public Float
53.88 M
Pieris Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.54
Market Cap
$229.07 M
Shares Outstanding
49.26 M
Public Float
53.08 M

Profile

Address
255 State Street
Boston Massachusetts 02109
United States
Employees -
Website http://www.pieris.com
Updated 07/08/2019
Pieris Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. It offers technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with an unmet medical need. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Financials

View All
Created with Highcharts 5.0.14Pieris Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.66669 8509 85014 05814 05822 79922 79917 64717 64726 75426 75420132014201520162017201805k10k15k20k25k30k
Created with Highcharts 5.0.14Pieris Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.12 42712 4275 3655 3652 9312 9315 8305 83025 27525 27529 10129 10120132014201520162017201805k10k15k20k25k30k35k

Stephen S. Yoder
President, Chief Executive Officer & Director
Peter Alec Kiener
Director